ADAR1 Capital Management »

Keros Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Keros Therapeutics (KROS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Keros Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Keros Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Keros Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $27M 688k 39.76

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Keros Therapeutics

Vanguard Group
OrbiMed Advisors
Braidwell
Darwin Global Management
T. Rowe Price Associates
Candriam Luxembourg S.C.A.
Citadel Advisors
Franklin Resources
ADAR1 Capital Management
Eventide Asset Management
Millennium Management
Deutsche Bank Aktiengesellschaft
Opaleye Management
Blue Owl Capital Holdings
Nantahala Capital Management

View all funds holding Keros Therapeutics